Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of action for…
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq:…
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+…
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6…
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
M42 signals genomics expansion with strategic partnership with Uzbekistan’s Ministry of Health on the Uzbek Genome Program Farhkodjon Tashpulatov, Uzbekistan’s…
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction…
- Unique dense breast tissue focus to drive expedited recruitment rates; modular clinical study design reduces time to PMA submission…
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global transmission electron microscope…
CRSA Joins Ryght Research Network to Accelerate Access to Novel Cancer Therapies LAGUNA BEACH, Calif., Jan. 28, 2025 /PRNewswire/ -- Ryght…